iTeos Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
iTeos Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q2 2024.
  • iTeos Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 14.6 %, a 3.81% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 14.6 -0.58 -3.81% Jun 30, 2024
Q1 2024 14.6 -4.33 -22.9% Mar 31, 2024
Q4 2023 13.4 -11.5 -46.1% Dec 31, 2023
Q3 2023 12.9 -22.9 -63.9% Sep 30, 2023
Q2 2023 15.2 -43.4 -74% Jun 30, 2023
Q1 2023 18.9 -42.8 -69.4% Mar 31, 2023
Q4 2022 24.9 -36.2 -59.3% Dec 31, 2022
Q3 2022 35.8 -12.1 -25.3% Sep 30, 2022
Q2 2022 58.7 +51.8 +758% Jun 30, 2022
Q1 2022 61.7 +54.2 +724% Mar 31, 2022
Q4 2021 61 Dec 31, 2021
Q3 2021 47.9 Sep 30, 2021
Q2 2021 6.83 Jun 30, 2021
Q1 2021 7.48 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.